A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study
Background: The United States Food and Drug Administration (US FDA) is responsible for ensuring public health by conducting a comprehensive assessment and approval of pharmaceuticals, medical devices, and food products. The federal agency conducts a thorough evaluation of drug safety and efficacy be...
Saved in:
Main Authors: | Ajay Kumar Shukla, Saurav Misra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | Journal of Pharmacy and Bioallied Sciences |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/jpbs.jpbs_730_25 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In Silico Study of FDA-Approved Drugs on <i>Leishmania infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis
by: Juan Diego Guarimata, et al.
Published: (2024-11-01) -
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01) -
Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria
by: Laiba Jalal, et al.
Published: (2025-07-01) -
Atrial Fibrillation Associated with Anticancer Drugs
by: O. D. Ostroumova, et al.
Published: (2020-12-01) -
Utilization and Determinants of Anticancer Drugs Under China&rsquo;s National Drug Price Negotiation Policy
by: Tuo B, et al.
Published: (2025-07-01)